Halozyme wins German injunction blocking Merck’s Keytruda distribution
While Merck can appeal, Halozyme said it expects the order to hold
While Merck can appeal, Halozyme said it expects the order to hold
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Growing patent filings and tier-2 innovators reflect expanding national research base
Subscribe To Our Newsletter & Stay Updated